LifeSci Capital analyst Rami Katkhuda has maintained their bullish stance on VYNE stock, giving a Buy rating on February 20.
Rami Katkhuda has given his Buy rating due to a combination of factors surrounding VYNE Therapeutics’ promising pipeline developments. The initiation of the Phase Ib trial for VYN202 in plaque psoriasis marks a significant step forward, with the study aiming to assess both safety and exploratory efficacy endpoints. The positive results from the earlier Phase Ia trial, which demonstrated a clean safety profile and effective inhibition of key inflammatory biomarkers, bolster confidence in VYN202’s potential as a treatment for autoimmune conditions.
Additionally, the ongoing Phase IIb study of repibresib (VYN201) in nonsegmental vitiligo is another critical factor. Previous trials showed promising clinical activity and a favorable safety profile, and the upcoming trial aims to further explore its benefits. The once-daily administration of repibresib, compared to the twice-daily regimen of the current standard of care, offers a potential advantage, particularly without a black-box warning. These developments, alongside VYNE’s strategic focus and financial metrics, underpin Katkhuda’s optimistic outlook on the company’s stock.
In another report released on February 20, TD Cowen also maintained a Buy rating on the stock with a $5.00 price target.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VYNE in relation to earlier this year.
Questions or Comments about the article? Write to editor@tipranks.com